152 related articles for article (PubMed ID: 22368921)
1. Chromogranin A--serum marker for prostate cancer.
Khan MO; Ather MH
J Pak Med Assoc; 2011 Jan; 61(1):108-11. PubMed ID: 22368921
[TBL] [Abstract][Full Text] [Related]
2. The prognostic value of serum chromogranin A and prostate specific antigen in prostate cancer patients for progression to the hormone resistance state.
Zissimopoulos A; Bantis A; Sountoulides P; Giannakopoulos S; Kalaitzis C; Agelonidou E; Touloupidis S
Hell J Nucl Med; 2009; 12(3):234-7. PubMed ID: 19936334
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of chromogranin A are not predictive of high-grade, poorly differentiated prostate cancer: results from an Italian biopsy cohort.
De Nunzio C; Albisinni S; Presicce F; Lombardo R; Cancrini F; Tubaro A
Urol Oncol; 2014 Feb; 32(2):80-4. PubMed ID: 23153859
[TBL] [Abstract][Full Text] [Related]
4. The prognostic role of immunohistochemical chromogranin a expression in prostate cancer patients is significantly modified by androgen-deprivation therapy.
Berruti A; Bollito E; Cracco CM; Volante M; Ciccone G; Porpiglia F; Papotti M; Scarpa RM; Dogliotti L
Prostate; 2010 May; 70(7):718-26. PubMed ID: 20087896
[TBL] [Abstract][Full Text] [Related]
5. Elevated serum chromogranin A precedes prostate-specific antigen elevation and predicts failure of androgen deprivation therapy in patients with advanced prostate cancer.
Chuang CK; Wu TL; Tsao KC; Liao SK
J Formos Med Assoc; 2003 Jul; 102(7):480-5. PubMed ID: 14517586
[TBL] [Abstract][Full Text] [Related]
6. [Plasma chromogranin-A (CgA)--a potential marker for diagnosis, monitoring and management of prostate cancer patients].
Leibovitch I; Pinthus Y; Sella BA; Ramon J
Harefuah; 2006 Jan; 145(1):25-9, 78. PubMed ID: 16450720
[TBL] [Abstract][Full Text] [Related]
7. The chromogranin-A (CgA) in prostate cancer.
Ranno S; Motta M; Rampello E; Risino C; Bennati E; Malaguarnera M
Arch Gerontol Geriatr; 2006; 43(1):117-26. PubMed ID: 16280180
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of serum markers for prostate cancer.
Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
[TBL] [Abstract][Full Text] [Related]
9. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease.
Berruti A; Mosca A; Tucci M; Terrone C; Torta M; Tarabuzzi R; Russo L; Cracco C; Bollito E; Scarpa RM; Angeli A; Dogliotti L
Endocr Relat Cancer; 2005 Mar; 12(1):109-17. PubMed ID: 15788643
[TBL] [Abstract][Full Text] [Related]
10. Implications of circulating chromogranin A in prostate cancer.
Hirano D; Minei S; Sugimoto S; Yamaguchi K; Yoshikawa T; Hachiya T; Kawata N; Yoshida T; Takahashi S
Scand J Urol Nephrol; 2007; 41(4):297-301. PubMed ID: 17763220
[TBL] [Abstract][Full Text] [Related]
11. Chromogranin A and biochemical progression-free survival in prostate adenocarcinomas submitted to radical prostatectomy.
Alessandro S; Vincenzo G; Maria AG; Stefano S; Alessandro G; Salvatore M; Vincenzo T; Franco DS
Endocr Relat Cancer; 2007 Sep; 14(3):625-32. PubMed ID: 17914093
[TBL] [Abstract][Full Text] [Related]
12. Changes in chromogranin a serum levels during endocrine therapy in metastatic prostate cancer patients.
Sasaki T; Komiya A; Suzuki H; Shimbo M; Ueda T; Akakura K; Ichikawa T
Eur Urol; 2005 Aug; 48(2):224-9; discussion 229-30. PubMed ID: 16005374
[TBL] [Abstract][Full Text] [Related]
13. Neuroendocrine differentiation in stage D2 prostate cancers.
Kamiya N; Suzuki H; Kawamura K; Imamoto T; Naya Y; Tochigi N; Kakuta Y; Yamaguchi K; Ishikura H; Ichikawa T
Int J Urol; 2008 May; 15(5):423-8. PubMed ID: 18452460
[TBL] [Abstract][Full Text] [Related]
14. Insulin-like growth factor 1, chromogranin A and prostate specific antigen serum levels in prostate cancer patients and controls.
Marszalek M; Wachter J; Ponholzer A; Leitha T; Rauchenwald M; Madersbacher S
Eur Urol; 2005 Jul; 48(1):34-9. PubMed ID: 15967249
[TBL] [Abstract][Full Text] [Related]
15. Potential clinical value of circulating chromogranin A in patients with prostate carcinoma.
Berruti A; Dogliotti L; Mosca A; Gorzegno G; Bollito E; Mari M; Tarabuzzi R; Poggio M; Torta M; Fontana D; Angeli A
Ann Oncol; 2001; 12 Suppl 2():S153-7. PubMed ID: 11762344
[TBL] [Abstract][Full Text] [Related]
16. [Combined assay of serum prostate specific antigen and chromogranin A helps diagnosis of prostate cancer].
Sun CC; Zheng W; Kong CZ; Wang X; Yang CM
Zhonghua Nan Ke Xue; 2006 Oct; 12(10):904-5, 909. PubMed ID: 17121020
[TBL] [Abstract][Full Text] [Related]
17. Plasma chromogranin A: clinical implications in patients with castrate resistant prostate cancer receiving docetaxel chemotherapy.
Sarkar D; Singh SK; Mandal AK; Agarwal MM; Mete UK; Kumar S; Mavuduru RS; Prasad R
Cancer Biomark; 2010-2011; 8(2):81-7. PubMed ID: 21896995
[TBL] [Abstract][Full Text] [Related]
18. Elevated circulating tissue inhibitor of metalloproteinase 1 (TIMP-1) levels are associated with neuroendocrine differentiation in castration resistant prostate cancer.
Gong Y; Chippada-Venkata UD; Galsky MD; Huang J; Oh WK
Prostate; 2015 May; 75(6):616-27. PubMed ID: 25560638
[TBL] [Abstract][Full Text] [Related]
19. Immunoassay and immunohistology studies of chromogranin A as a neuroendocrine marker in patients with carcinoma of the prostate.
Deftos LJ; Nakada S; Burton DW; di Sant'Agnese PA; Cockett AT; Abrahamsson PA
Urology; 1996 Jul; 48(1):58-62. PubMed ID: 8693652
[TBL] [Abstract][Full Text] [Related]
20. Prospective study on the relationship between clinical efficacy of secondary hormone therapy with flutamide and neuroendocrine differentiation in patients with relapsed prostate cancer after first line hormone therapy.
Hirano D; Hasegawa R; Satoh K; Mochida J; Yamanaka Y; Hirakata H; Yamaguchi K; Sugimoto S; Kawata N; Takahashi S
Scand J Urol; 2014 Oct; 48(5):436-44. PubMed ID: 24730473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
